The Brain Cancer Market is on a trajectory of substantial growth, with expectations set for it to reach an impressive US$ 4.9 billion by the year 2030, marking a significant leap from the US$ 2.9 billion recorded in 2023. This journey toward expansion is underpinned by a robust Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period. Brain cancer, a formidable adversary, entails the uncontrolled and abnormal proliferation of cells within the brain, posing a grave threat to health and well-being. It can manifest as either primary brain tumors, originating within the brain, or metastatic brain tumors, which spread to the brain from other parts of the body. Among adults, the most prevalent primary brain tumor types include gliomas, meningiomas, pituitary adenomas, vestibular schwannomas, and medulloblastomas.
The intricacy of treating brain cancer stems from the brain's critical role in the body and the presence of the blood-brain barrier, which restricts the delivery of therapeutic drugs. Available treatment modalities encompass surgical intervention, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with each option tailored to the specific characteristics of the tumor. Prognosis in brain cancer cases varies significantly, contingent upon factors such as tumor type, grade, and stage.
The Brain Cancer Market is meticulously segmented, considering tumor type, treatment modality, end-user demographics, and geographic region. Among these classifications, gliomas emerge as the largest segment, owing to their high incidence rate. Notably, North America asserts dominance in the market landscape, driven by a combination of factors, including a high prevalence of brain cancer cases and a well-established healthcare infrastructure that facilitates diagnosis and treatment.
In summary, the Brain Cancer Market reflects the formidable challenges posed by this complex disease and the ongoing efforts to address them. With a myriad of treatment options and a focus on improved diagnosis, this market stands at the forefront of advancements in oncology, endeavoring to enhance the prognosis and quality of life for those affected by brain cancer.
The incidence of primary malignant brain tumors is estimated to be around 28,000 new cases every year in the US. Glioblastoma is the most common and aggressive primary brain tumor in adults. The annual incidence rate of primary malignant brain and central nervous system (CNS) tumors is estimated to be 31,780 people in the US. Europe has an annual incidence of around 45,000. Several factors like exposure to radiation, genetic disorders, and immune conditions are associated with increased risk. The rising prevalence of brain tumors globally is a major factor driving growth.
There is a need for more effective therapies with lesser side-effects. Surgery, radiation, chemotherapy, targeted therapies are commonly used. Temozolomide, avastin are approved chemotherapies. Optune and NovoTTF-100A are novel device-based treatments. Immunotherapies by Bristol-Myers Squibb, Merck, Roche are upcoming. Personalized medicine and combination therapies are being evaluated. Radiosurgery is also gaining traction. Branded drug manufacturers dominate the market.
Brain Cancer Market Drivers
Increasing prevalence of brain tumors globally
The rising prevalence of brain tumors across the globe is a major factor driving the growth of the brain cancer market. As per statistics, around 28,000 new cases of primary malignant brain tumors are estimated to occur annually in the US. The annual incidence rate of primary malignant brain and central nervous system (CNS) tumors is estimated to be 31,780 people in the US alone. With improving healthcare infrastructure and diagnosis rates in emerging economies, more cases are being detected, leading to a growing patient pool globally. This presents significant opportunities for companies to develop novel diagnostics and therapies for brain cancer.
Improving diagnosis and screening tools
The increasing adoption of advanced imaging technologies such as MRI, CT, PET scans has enabled earlier detection of brain abnormalities and tumors. Molecular testing, genomic sequencing, and biomarkers allow accurate characterization of tumor cells, guiding targeted therapy. Companies are increasingly focusing on point-of-care and liquid biopsy tests for easier diagnosis. Government initiatives and rising awareness are also boosting diagnosis rates. Faster diagnosis is enabling timely treatment, thereby driving the brain cancer market growth.
Advances in radiation therapy and surgical techniques
Continuous advances are being made in radiation therapy including conformal radiation therapy, stereotactic radiosurgery, and proton beam therapy. These allow delivery of high doses to tumors while minimizing exposure to surrounding tissues. Robotic neurosurgery, intraoperative imaging, and navigation are also improving surgical outcomes. Minimally invasive techniques reduce hospital stays and complications. Due to these advances, radiation and surgery are becoming more precise and safer, boosting their adoption for brain cancer.
Development of targeted therapies and immunotherapies
The discovery of tumor-specific molecular targets has enabled the development of promising targeted drugs for various cancers including brain tumors. For example, BRAF and MEK inhibitors target mutations in melanoma brain metastases. Checkpoint inhibitor immunotherapies such as nivolumab, pembrolizumab have shown encouraging efficacy in clinical trials against glioblastoma. Several companies are working on antibody-drug conjugates, CAR T-cell therapies, and combination regimens as well. Such innovations are expected to significantly improve brain cancer treatment and survival rates.
The market size in 2023
US$ 2.9 Bn
CAGR (2023 - 2030)
The revenue forecast in 2030
US$ 4.9 Bn
Base year for estimation
Revenue in USD Million, and CAGR from 2021 to 2030
By Treatment Type: Chemotherapy, Targeted drug therapy, Immunotherapy, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
Hoffmann-La Roche, AbbVie, Amgen, Merck & Co., Bristol-Myers Squibb, Novocure, Varian Medical Systems, Elekta, Accuray, Ion Beam Applications, Mevion Medical Systems, Hitachi, Philips Healthcare, GE Healthcare, Siemens Healthineers, Canon Medical Systems, Nordion, Isoray, ViewRay, Brainlab
Brain Cancer Market Opportunities
Combination therapies for better outcomes
The potential of using combination regimens comprising chemotherapy, targeted drugs, immunotherapy together is being increasingly evaluated in clinical trials for brain tumors. Such combinations synergistically target multiple cancer pathways and mechanisms, overcoming resistance and enhancing efficacy compared to single drugs. For instance, combining BRAF and MEK inhibitors improved survival in melanoma brain metastases. There are also trials on combinations of chemotherapy and immunotherapy. Combination strategies could thus provide more durable responses and become the backbone of brain cancer treatment.
Expanding applications of nanotechnology
Nanotechnology offers unique advantages for crossing the blood-brain barrier and targeted drug delivery to brain tumors. Nanoparticles conjugated with ligands precisely bind to receptors overexpressed on cancer cells. Companies are developing various nanoparticles for targeted delivery of small molecule drugs, chemotherapy, proteins, nucleic acids and other payloads. Furthermore, gold and magnetic nanoparticles enable contrast enhancement and thermal ablation of tumors. The expanding nanomedicine pipeline thus presents immense opportunities for advancements in brain cancer therapies.
Leveraging big data and artificial intelligence
Large datasets from electronic health records, genomic databases, neuroimaging, and clinical trials are becoming available. The application of big data analytics and AI can glean insights for understanding disease mechanisms, identifying prognostic biomarkers, and predicting optimal treatments based on patient characteristics. AI also shows utility in radiotherapy planning, customized surgical simulation models, and analyzing pathological images. Thus, big data and AI have the potential to revolutionize diagnosis, treatment personalization and overall management for brain cancer patients.
Increasing research on cancer stem cells
Cancer stem cells constitute a small subset of cells capable of self-renewal and differentiation, contributing to tumor heterogeneity, recurrence and resistance. Targeting pathways involved in the survival and propagation of brain tumor stem cells offers a promising approach to achieve lasting remission and improved survival. Ongoing research on drugs inhibiting proteins such as CD133, Bmi1, Sox2 is expected to eventually translate into clinical applications. Eliminating cancer stem cells could become a new paradigm for more effective and durable brain cancer therapies.
Brain Cancer Market Trends
Adoption of minimally invasive techniques gaining traction
Minimally invasive approaches are being increasingly adopted for biopsy, surgery and treatment of brain tumors, improving clinical outcomes. Stereotactic needle biopsies allow accurate sampling of tissue with minimal trauma. Endoscopy techniques enable removal of certain tumors through small holes avoiding open surgery. Radiosurgery provides precisely targeted radiation minimizing exposure and damage to surrounding tissue. Robotic neurosurgery further allows complex procedures with greater precision and smaller incisions. Due to shorter hospitalization and lower complication rates, minimally invasive techniques are witnessing rising utilization for brain cancer.
Development of targeted drug delivery platforms
Targeted drug delivery is emerging as an active area of pharmaceutical research and development for brain tumors. Novel carrier systems such as antibodies, peptides, nanoparticles and stem cells are being designed to selectively bind to overexpressed receptors on tumor cells and deliver their drug payload specifically to the tumor site. This improves therapeutic efficacy while reducing off-target effects and toxicity. For instance, GlaxoSmithKline’s antibody-drug conjugate belantamab mafodotin is FDA approved for treating multiple myeloma. Similar targeted platforms are expected to enhance chemotherapy delivery across the blood-brain barrier for various brain cancers.
Investigational drugs with breakthrough therapy designation
The FDA grants breakthrough therapy designation to expedite development of investigational drugs showing substantial improvement over available therapies for serious conditions. Several brain cancer drugs have received this status recently including PD-1 inhibitors pembrolizumab, nivolumab for glioblastoma, selinexor for gliomas, and 177Lu-omburtamab-DTPA for pediatric CNS tumors. The breakthrough designation allows close FDA guidance and accelerated approval, leading to faster availability of novel therapies for patients with an unmet need. This trend will continue driving therapeutic innovation for brain cancer.
Rising industry and research collaborations
Recognizing the need for multi-disciplinary expertise, there has been a surge in collaborations between pharmaceutical companies, academia, and technology firms to accelerate brain cancer drug discovery and development. Public-private partnerships are also growing to pool resources and share risks. For instance, the GBM AGILE international clinical trial brings together regulators, biopharma and academic centers. Precompetitive consortiums allow sharing of cancer genomic datasets. Such synergistic collaborations will be vital to overcome research bottlenecks and achieve common goals of developing more effective personalized brain cancer therapies.
Brain Cancer Market Restraints
Failure of clinical trials
A major challenge in brain cancer drug development is the high rate of failure of investigational drugs in clinical trials. For instance, around 97% of glioblastoma clinical trials do not meet their primary endpoint. This is attributed to factors such as molecular heterogeneity of tumors, poor correlation between preclinical models and human trials, toxicity, and inadequate trial design. Failed clinical trials result in huge losses for pharmaceutical companies, posing a significant barrier to expanding the brain cancer treatment pipeline and the growth of this market.
Strict regulations for new drug approvals
The regulatory requirements for approval of new oncology drugs are stringent, requiring large investments of time and resources from pharmaceutical companies. Approval of new molecular entities for brain cancer requires demonstration of significant improvement in overall or progression-free survival in randomized controlled trials along with supportive data on safety and quality of life. Additional trials may be mandated for specific age groups like pediatrics. Delays in regulatory review and clinical development prolong the market launch of new brain cancer therapies.
High costs of targeted therapies
Many branded targeted therapies used for precision treatment of brain tumors like glioblastoma are expensive, with annual costs reaching up to USD 100,000. The high costs pose a significant economic burden for patients and healthcare systems, negatively impacting adoption and market access. Lack of favorable reimbursement coverage also limits access to targeted drugs. Furthermore, cost-effectiveness is being increasingly scrutinized by payers and regulators during approval decisions. Addressing the prohibitive pricingissue is therefore essential for the wider adoption of emerging precision medicine-based approaches for brain cancer.
August 2022 - FDA approved adagrasib by Mirati Therapeutics for non-small cell lung cancer with KRAS mutation
January 2022 - Lytix Biopharma gained FDA fast track designation for LTX-315 for treating head and neck squamous cell carcinoma
November 2021 - FDA approved Mobocertinib by Takeda Pharmaceutical for EGFR mutant non-small cell lung cancer
June 2021 - FDA approved Pembrolizumab + Lenvatinib combination by Merck and Eisai for advanced endometrial carcinoma
Merck and Eisai
May 2021 - FDA approved Belantamab mafodotin by GlaxoSmithKline for relapsed/refractory multiple myeloma
Regional Dynamics of the Brain Cancer Market
The Brain Cancer Market exhibits notable regional variations, influenced by factors such as disease prevalence, healthcare infrastructure, research funding, and the presence of key industry players. A closer examination of regional insights unveils key growth dynamics.
- North America: Pioneering Advances North America takes the lead, accounting for a substantial market share of 41.5% in 2022. This region's dominance is propelled by several factors, including a high prevalence of brain tumors, a well-established healthcare infrastructure, robust diagnosis rates, the presence of major industry players, and the continuous introduction of new products into the market. North America's progressive approach and substantial investments have elevated it to the forefront of the Brain Cancer Market.
- Europe: A Strong Contender Europe secures its position as the second-largest market for brain cancer, contributing a significant market share of 29.2% in 2022. The growth in this region is driven by elevated healthcare expenditure and substantial research funding. Europe's commitment to advancing brain cancer research and treatment options underscores its significance in the market.
- Asia Pacific: Emerging as a Growth Hub The Asia Pacific region is poised to witness the fastest growth in the Brain Cancer Market, with a remarkable Compound Annual Growth Rate (CAGR) of 9.1% during the period from 2023 to 2030. This growth surge is attributed to factors such as improving healthcare infrastructure, rising awareness about brain cancer, and increasing investments in Research and Development (R&D) initiatives. The Asia Pacific region represents a dynamic growth hub, capturing a market share of 16.8%.
- Other Regions: Contributing to Global Growth While holding smaller market shares, Latin America and the Middle East & Africa regions play integral roles in the global Brain Cancer Market. Latin America contributes with a market share of 7.1%, while the Middle East and Africa region accounts for 5.4%. These regions, though relatively smaller in market size, contribute to the global landscape and offer potential avenues for growth.
In summary, regional variations in disease prevalence, healthcare infrastructure, research focus, and investments significantly shape the dynamics of the Brain Cancer Market. North America leads the way with pioneering advances, while Europe strengthens its position through substantial research funding. The Asia Pacific region emerges as a vibrant growth center, and Latin America and the Middle East & Africa continue to contribute to the global market landscape.
By Treatment Type
- Targeted drug therapy
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
- Hoffmann-La Roche
- Merck & Co.
- Bristol-Myers Squibb
- Varian Medical Systems
- Ion Beam Applications